No Baby Blisters has announced an expansion of its two-pronged effort to support families affected by epidermolysis bullosa (EB) while advancing research toward an affordable treatment for the rare genetic disorder, which causes severe skin fragility and chronic pain.
More details can be found at https://nobabyblisters.org/#fast-cure-plan
Epidermolysis bullosa is estimated to affect around 500,000 people worldwide, according to the Dystrophic Epidermolysis Bullosa Research Association (DEBRA). The condition is characterized by skin that blisters and tears from minor friction, caused by defects in the proteins that bind skin layers together. Current treatment options focus on wound care and pain management, and there is no cure, leaving families to manage a lifelong condition with limited medical support.
No Baby Blisters states that addressing this gap requires immediate intervention and sustained research efforts. Through its Hero Guardian Angel program, the organization says it provides families with access to essential supplies such as specialized bandages and pain management resources, helping to reduce daily suffering and complications associated with the condition.
"Families are dealing with a condition that has no cure and limited support systems," said founder Aaron Tabor, MD. "Our work is focused on relieving that burden now, while also pursuing solutions that can change the long-term outlook for these children."
The organization's Fast Cure Plan includes research into gene-based therapies aimed at correcting the underlying protein defects, as well as complementary approaches designed to reduce inflammation and improve skin healing.
One of the primary challenges in EB research, No Baby Blisters explains, has been the cost and accessibility of potential treatments. The organization says its research is designed with affordability in mind, with the goal of ensuring that any future treatment can reach patients globally.
"Our objective is not just to find a treatment, but to make sure it's practical and accessible," Dr. Tabor added. "A solution only matters if it can reach the children who need it."
The organization notes that its medical team draws on experience in clinical research and regulatory pathways, with a focus on advancing studies toward real-world applications. No Baby Blisters adds that its work has been referenced in peer-reviewed research, reflecting ongoing contributions to the broader scientific understanding of EB.
No Baby Blisters is a nonprofit organization founded by Aaron Tabor, MD, dedicated to supporting children with epidermolysis bullosa and advancing research toward an accessible, long-term treatment for the condition. The organization operates two core programs: the Hero Guardian Angel program, which provides families with essential medical supplies and pain management resources, and the Fast Cure Plan, a research initiative focused on gene-based therapies and complementary approaches to improve skin healing. No Baby Blisters' work has been referenced in peer-reviewed research related to EB.
Those interested in learning more can visit https://nobabyblisters.org/
No Baby Blisters
731 Chapel Hills Drive
Colorado Springs
Colorado
80920
United States
